Cellectis Sa Stock Performance
| CMVLF Stock | USD 2.54 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Cellectis are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cellectis SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable essential indicators, Cellectis is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 241.1 M | |
| Total Cashflows From Investing Activities | 7.3 M |
Cellectis |
Cellectis Relative Risk vs. Return Landscape
If you would invest 254.00 in Cellectis SA on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Cellectis SA or generate 0.0% return on investment over 90 days. Cellectis SA is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Cellectis, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cellectis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectis' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cellectis SA, and traders can use it to determine the average amount a Cellectis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CMVLF |
Based on monthly moving average Cellectis is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cellectis by adding Cellectis to a well-diversified portfolio.
Cellectis Fundamentals Growth
Cellectis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cellectis, and Cellectis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectis Pink Sheet performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 82.79 M | |||
| Shares Outstanding | 55.59 M | |||
| Price To Earning | (13.64) X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.79 X | |||
| Revenue | 57.29 M | |||
| EBITDA | (103.2 M) | |||
| Cash And Equivalents | 153.13 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 18.77 M | |||
| Debt To Equity | 0.52 % | |||
| Book Value Per Share | 3.00 X | |||
| Cash Flow From Operations | (104.56 M) | |||
| Earnings Per Share | (2.95) X | |||
| Total Asset | 382.08 M | |||
| Retained Earnings | (206 M) | |||
| Current Asset | 297 M | |||
| Current Liabilities | 58 M | |||
About Cellectis Performance
By analyzing Cellectis' fundamental ratios, stakeholders can gain valuable insights into Cellectis' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cellectis has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cellectis has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people.Things to note about Cellectis SA performance evaluation
Checking the ongoing alerts about Cellectis for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cellectis SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellectis SA generated a negative expected return over the last 90 days | |
| The company reported the revenue of 57.29 M. Net Loss for the year was (114.2 M) with profit before overhead, payroll, taxes, and interest of 34.18 M. | |
| Cellectis SA has accumulated about 153.13 M in cash with (104.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Cellectis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectis' stock is overvalued or undervalued compared to its peers.
- Examining Cellectis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellectis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellectis' pink sheet. These opinions can provide insight into Cellectis' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cellectis Pink Sheet analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |